Welcome to our dedicated page for Nuvalent SEC filings (Ticker: NUVL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Phase 1 dose-escalation data, cash-runway forecasts, and share-based compensation tables often stretch Nuvalent’s disclosures far beyond 200 pages. Finding where the company reports trial enrollment numbers or how much dilution new equity raises might cause can feel like searching for a molecule in a lab beaker. If you have ever typed “Nuvalent insider trading Form 4 transactions” into Google, you already know the challenge. That complexity is why investors need Nuvalent SEC filings explained simply, without losing the nuance that drives valuation for a clinical-stage oncology company.
Stock Titan’s AI tackles the hard chemistry of regulatory language. Our engine turns each Nuvalent annual report 10-K simplified and every Nuvalent quarterly earnings report 10-Q filing into plain-English briefs that spotlight pipeline progress, R&D spend, and cash-burn trends. Real-time alerts push Nuvalent Form 4 insider transactions real-time to your dashboard, so you can see Nuvalent executive stock transactions Form 4 within minutes of EDGAR posting. Interactive modules map 8-K material events to specific trial milestones, letting you skim Nuvalent 8-K material events explained instead of scrolling line by line.
Want deeper context? Click into any filing and our AI highlights where option grants appear in a Nuvalent proxy statement executive compensation section, or generates side-by-side Nuvalent earnings report filing analysis across quarters. You will also find:
- Segmented R&D spend tied to ALK, ROS1, and HER2 programs
- Cash-runway projections based on the latest 10-Q
- Insider purchase patterns before data readouts
Understanding Nuvalent SEC documents with AI means less time decoding tables and more time deciding if the next kinase-inhibitor breakthrough fits your portfolio. Real-time updates, comprehensive coverage, and expert analysis—all in one place.
Nuvalent officer Alexandra Balcom filed Form 144 indicating intent to sell 129,480 shares of Class A common stock with an aggregate market value of $10,358,400 through J.P. Morgan Securities. The planned sale represents approximately 0.2% of the company's 66.37 million outstanding shares.
The securities to be sold were acquired through two transactions:
- 122,396 shares via stock option exercise on June 27, 2025
- 7,084 shares from RSU vesting on January 6, 2025
The sale is being executed under a Rule 10b5-1 trading plan adopted on December 12, 2024. Some transactions will involve cashless option exercises within 3 months of filing. Notably, Balcom has not sold any company securities in the past 3 months. The filing includes standard attestation that the seller has no knowledge of material adverse non-public information.
Nuvalent Officer Darlene Noci has filed Form 144 indicating intent to sell 12,000 shares of Class A Common Stock through J.P. Morgan Securities, with an aggregate market value of $948,840. The sale is planned for June 26, 2025, on the NASDAQ exchange.
The securities were acquired through a stock option exercise on June 26, 2025. The filing reveals a consistent pattern of previous sales by Noci over the past three months:
- March 27, 2025: 4,000 shares ($292,482)
- April 29, 2025: 4,000 shares ($298,232)
- May 29, 2025: 4,000 shares ($285,238)
The sales are part of a Rule 10b5-1 trading plan adopted on November 18, 2024, and will be executed through cashless option exercises within three months of the filing date. Total shares outstanding: 66,373,511.
Insider Trading Alert: James E. Flynn and Deerfield Management Company reported significant beneficial ownership changes in Nuvalent (NUVL) through multiple transactions on June 18, 2025.
Key Transaction Details:
- Two directors affiliated with Deerfield Management received RSUs: Cameron Wheeler and Joseph Pearlberg each granted 2,647 shares vesting by June 18, 2026
- Both directors received stock options to purchase 4,147 shares each at $75.53/share, expiring June 18, 2035
- Deerfield entities maintain substantial holdings: Deerfield Private Design Fund IV and Deerfield Healthcare Innovations Fund each own 8,670,512 shares
- Deerfield Partners holds 650,000 shares
All securities are held indirectly through Deerfield Management Company, with James Flynn serving as the sole member of the general partner entities. The filing indicates significant institutional control through multiple investment vehicles and board representation.
Cameron Wheeler, Director at Nuvalent (NUVL), reported two significant equity transactions on June 18, 2025:
- Acquired 2,647 Restricted Stock Units (RSUs) at $0.00, convertible to Class A Common Stock. These RSUs vest fully on June 18, 2026, or at the next annual stockholder meeting
- Received stock options to purchase 4,147 shares at an exercise price of $75.53 per share, expiring June 18, 2035
Important disclosure: Wheeler, a partner at Deerfield Management Company, L.P., holds these securities for the benefit of Deerfield Management and disclaims beneficial ownership. Following these transactions, Wheeler directly owns 5,146 shares and 4,147 stock options. Both the RSUs and options are subject to continued service requirements.
Director Sapna Srivastava of Nuvalent received new equity compensation on June 18, 2025, consisting of:
- 2,647 Restricted Stock Units (RSUs) convertible to Class A Common Stock at $0.00, bringing total direct RSU ownership to 5,146 shares
- 4,147 Stock Options with strike price of $75.53, exercisable until June 18, 2035
Both the RSUs and stock options vest in full on the earlier of June 18, 2026 or the next annual stockholder meeting, contingent on continued service. This grant appears to be part of the company's director compensation program. The filing was submitted through an attorney-in-fact on June 20, 2025.
Nuvalent Director Matthew Shair reported multiple securities transactions on June 18, 2025. The transactions include:
- Acquisition of 2,647 restricted stock units (RSUs) at $0.00, convertible to Class A Common Stock. These RSUs vest fully by June 18, 2026 or the next annual stockholder meeting
- Grant of stock options to purchase 4,147 shares at $75.53 per share, expiring June 18, 2035
Following these transactions, Shair directly owns 1,429,844 shares of Class A Common Stock and indirectly controls 216,522 shares through the Matthew D. Shair 2021 Irrevocable Family Trust. The compensation package appears to be part of standard director remuneration, with both RSUs and options subject to one-year vesting periods tied to continued service.
Nuvalent director Anna Protopapas received new equity compensation grants on June 18, 2025, consisting of:
- 2,647 Restricted Stock Units (RSUs) of Class A Common Stock at $0.00, which vest in full on the earlier of June 18, 2026, or the next annual stockholder meeting
- 4,147 Stock Options with a strike price of $75.53, exercisable until June 18, 2035, following the same vesting schedule as the RSUs
Following these transactions, Protopapas directly owns 5,146 shares of Class A Common Stock and 4,147 stock options. These grants appear to be part of the company's director compensation program, with a one-year vesting period tied to continued service on the board.
Joseph Pearlberg, Director at Nuvalent (NUVL), reported two significant equity transactions on June 18, 2025:
- Acquired 2,647 Restricted Stock Units (RSUs) at $0.00, convertible to Class A Common Stock. These RSUs will fully vest on June 18, 2026, or at the next annual stockholder meeting, bringing total direct ownership to 5,146 shares
- Received stock options to purchase 4,147 shares at an exercise price of $75.53, expiring June 18, 2035. Options follow the same vesting schedule as the RSUs
Important disclosure: Pearlberg, an employee of Deerfield Management Company, holds these securities for Deerfield's benefit and direction, disclaiming personal beneficial ownership. This suggests an institutional relationship between Deerfield Management and Nuvalent's governance structure.
FAQ
What is the current stock price of Nuvalent (NUVL)?
What is the market cap of Nuvalent (NUVL)?
What is Nuvalent, Inc focused on?
How does Nuvalent differentiate itself in oncology drug development?
Which cancer types are the primary focus for Nuvalent's therapies?
What is the significance of a brain-penetrant therapy?
How does Nuvalent's approach address resistance mutations?
What stage is Nuvalent currently at in its drug development process?
How does Nuvalent ensure the safety and efficacy of its therapies?
